Edgewise Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-4.6%projected annual EPS growth
Analyst Coverage
13analysts covering
FY Revenue (est.)
$139.6Mnext fiscal year
FY EPS (est.)
$1.39next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| GRAND CANYON Phase 3 Becker Muscular Dystrophy Top-Line Data Announcement | 31 Dec 2026 |
| Initiation of EDG-7500 Phase 3 Trial in HCM | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
GRAND CANYON Phase 3 Becker Muscular Dystrophy Trial Enrollment & Completion Quarterly100.0Target: Complete 18-month treatment period and report top-line results
EDG-7500 Phase 2 CIRRUS-HCM Part D 12-Week Efficacy & Safety Data Quarterly100.0Target: Report positive top-line results demonstrating functional and biomarker improvements
Cash Runway and Capital Reserves Quarterly560MTarget: Maintain sufficient liquidity to fund operations into late 2027
Watch Items
- Initiation of Phase 3 Trial for EDG-7500 in Hypertrophic Cardiomyopathy (HCM)Trigger: End-of-Phase-2 meeting with the FDA in H2 2026Action: Finalize Phase 3 trial design and initiate patient dosing by Q4 2026
- New Drug Application (NDA) Submission for Sevasemten in Becker Muscular DystrophyTrigger: Positive top-line GRAND CANYON Phase 3 data in Q4 2026Action: Prepare and submit NDA to the FDA in H1 2027
- Phase 3 Trial Design and Initiation for Sevasemten in Duchenne Muscular Dystrophy (DMD)Trigger: Finalization of trial design in H2 2026Action: Launch Phase 3 trial in DMD patients
Research as of 20 Jun 2026